Calbo Francisco, Dal-Ré Rafael, Díez-Delgado Javier, Oña Salvador, Sánchez-Prados Francisco, García-Corbeira Pilar
Departamento de Medicina Preventiva, Hospital Carlos Haya, Málaga, Spain.
Med Clin (Barc). 2002 Jan 19;118(1):1-4. doi: 10.1016/s0025-7753(02)72265-3.
The diphtheria-tetanus-whole-cell pertussis (DTPw) vaccine is being replaced in Western countries,and in several Spanish Autonomous Communities, by the diphtheria-tetanus-acellular pertussis (DTPa) vaccine. Although the administration of booster doses of DTPw or DTPa and Haemophilus influenzae type b conjugate (Hib) vaccines to toddlers is a current practice ina number of countries, there are few data comparing the reactogenicity profiles of their administration as a single injection.
An open,prospective, randomised, multicentre trial was conducted to compare the reactogenicity profile of a single injection of DTPa and Hib vaccines (DTPa/Hib) with that of a single injection of DTPw and Hib vaccines (DTPw/Hib) as booster doses to toddlers--previously primed with DTPw and Hib vaccines. 200 children (15.1 +/-1.0 months-old) were randomised to receive DTPa/Hib (group 1;n = 101) or DTPw/Hib (group 2; n = 99) and followed up to 30 days post-vaccination. All subjects received the oral polio vaccine concomitantly. Local and general symptoms were recorded by parents on diary cards.
Incidences of any local reaction and any general symptom <
The administration of DTPa/Hib as a single injection leads to a better reactogenicity profile than the administration of DTPw/Hib, also as a single injection, as booster doses to toddlers primed with DTPw and Hib vaccines.
在西方国家以及西班牙的几个自治区,白喉-破伤风-全细胞百日咳(DTPw)疫苗正被白喉-破伤风-无细胞百日咳(DTPa)疫苗所取代。尽管在一些国家,给幼儿接种DTPw或DTPa以及b型流感嗜血杆菌结合疫苗(Hib)的加强剂量是目前的一种做法,但很少有数据比较它们单次注射时的反应原性情况。
开展了一项开放、前瞻性、随机、多中心试验,以比较单次注射DTPa和Hib疫苗(DTPa/Hib)与单次注射DTPw和Hib疫苗(DTPw/Hib)作为加强剂量给先前已接种过DTPw和Hib疫苗的幼儿时的反应原性情况。200名儿童(15.1±1.0个月大)被随机分为接受DTPa/Hib(第1组;n = 101)或DTPw/Hib(第2组;n = 99),并在接种疫苗后随访30天。所有受试者同时接种口服脊髓灰质炎疫苗。家长在日记卡上记录局部和全身症状。
第2组报告的任何可能与疫苗接种相关/疑似与疫苗接种相关的局部反应和任何全身症状的发生率均高于第1组(p < 0.0001)。第1组和第2组分别有29%和66%的受试者报告注射部位疼痛(p < 0.0001)。第2组(15%)比第1组(1%)更频繁地记录到肢体移动时孩子因疼痛而哭闹的情况(p < 0.0001)。任何肿胀(第1组16%,第2组30%)和肿胀>20mm的患病率差异具有统计学意义(p≤0.012)。第1组和第2组受试者分别有17%和41%报告发热(直肠温度≥38摄氏度)(p < 0.0001)。DTPw/Hib组的烦躁、食欲不振和不安也更频繁地被报告且具有统计学意义(至少p = 0.015)。仅14%的病例(第1组9例,第2组19例;p = 0.0424)预防性使用了镇痛药/退热药。接种疫苗后使用退热药治疗在第2组(27例)显著多于第1组(8例)(p < 0.015)。
作为加强剂量给先前已接种过DTPw和Hib疫苗的幼儿单次注射DTPa/Hib比单次注射DTPw/Hib具有更好的反应原性情况。